BMRN Q4 2023 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$646M+20.2% YoY

Gross Profit

$511M79.0% margin

Operating Income

$14M2.2% margin

Net Income

$20M3.2% margin

EPS (Diluted)

$0.11

QoQ Revenue Growth

+11.2%

Cash Flow

Operating Cash Flow

$27M

Free Cash Flow

-$9M

Stock-Based Comp.

$55M

Balance Sheet

Total Assets

$6.8B

Total Liabilities

$1.9B

Stockholders' Equity

$5.0B

Cash & Equivalents

$755M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$646M	$538M	+20.2%
Gross Profit	$511M	$410M	+24.5%
Operating Income	$14M	-$25M	+158.0%
Net Income	$20M	-$249,000	+8282.7%

Revenue Segments

Product

$633M58%

Enzyme Product

$448M41%

Royalty And Other

$13M1%